4//SEC Filing
ROBINS CHAD M 4
Accession 0001062993-25-002744
CIK 0001478320other
Filed
Feb 17, 7:00 PM ET
Accepted
Feb 18, 8:21 PM ET
Size
19.9 KB
Accession
0001062993-25-002744
Insider Transaction Report
Form 4
ROBINS CHAD M
DirectorCEO and Chairman
Transactions
- Sale
Common Stock
2025-02-14$8.46/sh−158,921$1,344,472→ 2,576,701 total - Exercise/Conversion
Common Stock
2025-02-18$6.32/sh+211,160$1,334,531→ 2,787,861 total - Sale
Common Stock
2025-02-18$8.50/sh−211,160$1,794,860→ 2,576,701 total - Exercise/Conversion
Common Stock
2025-02-13$6.32/sh+100,287$633,814→ 2,676,988 total - Exercise/Conversion
Stock Option (right to buy)
2025-02-14−158,921→ 496,347 totalExercise: $6.32Exp: 2025-06-09→ Common Stock (158,921 underlying) - Exercise/Conversion
Stock Option (right to buy)
2025-02-18−211,160→ 285,187 totalExercise: $6.32Exp: 2025-06-09→ Common Stock (211,160 underlying) - Sale
Common Stock
2025-02-13$8.44/sh−100,287$846,422→ 2,576,701 total - Exercise/Conversion
Common Stock
2025-02-14$6.32/sh+158,921$1,004,381→ 2,735,622 total - Exercise/Conversion
Stock Option (right to buy)
2025-02-13−100,287→ 655,268 totalExercise: $6.32Exp: 2025-06-09→ Common Stock (100,287 underlying)
Footnotes (5)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 26, 2024. The option expires on June 9, 2025.
- [F2]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.56, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F3]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.69, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F4]The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to 8.91, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
- [F5]The option is fully vested and exercisable.
Issuer
Adaptive Biotechnologies Corp
CIK 0001478320
Entity typeother
Related Parties
1- filerCIK 0001780649
Filing Metadata
- Form type
- 4
- Filed
- Feb 17, 7:00 PM ET
- Accepted
- Feb 18, 8:21 PM ET
- Size
- 19.9 KB